Navigation Links
Kalorama: Yellen Comments on Biotechnology Sector At Odds With Venture Capital Trends
Date:8/4/2014

NEW YORK, Aug. 4, 2014 /PRNewswire/ -- Despite the stir caused by recent comments by Federal Reserve Chair Janet Yellen regarding the state of the biotechnology sector, Kalorama Information sees potential for growth based on the substantial investments in venture capital that came into the biotech market in 2012-2013. Kalorama's Biotech Funding Deals and Partnerships notes that biotech investment has increased significantly in the past few years and that 2013 saw a noticeable spike. In the last few years, this has resulted in a complex series of deals and transactions involving major players in the industry, as investors invest in proven companies on new science and technology initiatives that have potential in the clinic. 

Fed Chair Janet Yellen commented regarding the biotechnology sector in testimony to Congress on July 15th (http://www.federalreserve.gov/monetarypolicy/files/20140715_mprfullreport.pdf), stating that "valuation metrics in some sectors do appear substantially stretched—particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year."  This comment has been much discussed in the media, and some media outlets and business pundits have questioned whether the comments have affected biotechnology stocks. 

The healthcare market research firm notes that the statement did not take into account information from venture capital markets, which have for the most part backed biotechnology. 

"While Federal Reserve Chair Yellen's comments were directed at equity markets, venture capital spends are another way to judge a sector's merit," said Bruce Carlson, Publisher of Kalorama Information.  "One out of every eight dollars invested in companies is invested in biotech.  For key players in the biotechnology sector, the landscape for investing remains fertile."

Kalorama's Biotech Funding Deals and Partnerships notes significant transactions from 2011 to 2014 involving major companies such as Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. This report reviews the nature and direction of funding trends, and outlines the important role that investments play in moving technology into the marketplace.

Kalorama Information's report, Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions, provides analysis of both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the marketplace as approved therapies, especially if they address unmet medical needs. The report can be found at KI: http://www.marketresearch.com/redirect.asp?progid=86478&url=http%3A%2F%2Fwww%2Ekaloramainformation%2Ecom%2FBiotech%2DFunding%2DDeals%2D8169354%2F  

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.

Contact:
Bruce Carlson
bcarlson@kaloramainformation.com
(212)-807-2622
www.KaloramaInformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634


'/>"/>
SOURCE Kalorama Information
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. WestPark Capitals Michael Wechsler Comments on the Life Insurance Market
2. House to Vote on Post-Sandy Mold Relief Fund Next Week; Dr Mold Network Comments Amount is Truly Needed by Hurricane Victims
3. Ian Somerhalder Raises Big Money for the Environment; Optimal Chemical Comments His Effort Proves He's a True Green Celebrity
4. Jennifer Aniston's People's Choice Awards Dress Worries Animal Welfare Advocates; Going Green News Site My Cleaning Products Comments It Was a Bad Pick
5. Probiotic Action Comments on Acne Statistics by WebMD
6. Can You Be Too Old for Acne? Probiotic Action comments on news from The Vitals Blog
7. An article from Bloomberg.com discusses Ban on a Common Acne Treatment; Probiotic Action Comments On the product Ban
8. Probiotic Action Comments on Huffington Post’s, Best Foods for Acne and offers Advice on Foods to Balance your Body
9. Probiotic Comments on Claims that Plant-Based Oils Are the Best Acne Treatments
10. Acne Treatment Brand, Probiotic Action, Comments on the Use of a Virus to Treat Acne
11. Probiotic Action Comments on New Findings on Using Light Therapy to Fight Acne
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):